Immediate Precision, Optimal Care
Acurion (formerly io9) develops OncoGaze™, an AI-powered platform that reads tumor biology from standard pathology slides to identify clinically actionable biomarkers in minutes. The platform currently detects homologous recombination deficiency (HRD) in breast and ovarian cancer, enabling oncologists to identify up to three times more patients eligible for life-extending therapies. Validated in over 1,400 patients and published in the Journal of Clinical Oncology, Acurion raised a $4.3M oversubscribed seed round led by TK & Partners.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2026
Create a free account to see which investors have funded this company.
Create Free Account
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...
Anduril Industries is a defense technology company with a mission to transform US and allied mili...
